Leerink lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy following program updates in October. The firm notes that while evidence of expression was present, clinical benefit is yet to be determined. Updated Cohort 1 data are expected in the first half of 2025, while initial Cohort 2 and MyClimb natural history data are expected in 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Piper bullish on Tenaya, says initial MyPEAK-1 data de-risks higher dosing
- Tenaya Therapeutics Reports Promising TN-201 Trial Results
- Tenaya Therapeutics’ Senior VP Resigns for New Opportunity
- Tenaya reported early data from first cohort of patients in MyPEAK-1 trial
- Tenaya Therapeutics to announce initial data from Phase 1b/2 trial of TN-201